Evidence map›Paper›PMID 25319010›Full record

ArticleMolecular cancer research : MCR2015

Prometastatic NEDD9 Regulates Individual Cell Migration via Caveolin-1-Dependent Trafficking of Integrins.

Polina Y Kozyulina, Yuriy V Loskutov, Varvara K Kozyreva, Anuradha Rajulapati, Ryan J Ice, Brandon C Jones, Elena N Pugacheva

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Polina Y KozyulinaDepartment of Biochemistry, School of Medicine, West Virginia University, Morgantown, West Virginia. Institute of Cytology Russian Academy of Sciences, St. Petersburg, Russia.
Yuriy V LoskutovMary Babb Randolph Cancer Center, School of Medicine, West Virginia University, Morgantown, West Virginia.
Varvara K KozyrevaMary Babb Randolph Cancer Center, School of Medicine, West Virginia University, Morgantown, West Virginia.
Anuradha RajulapatiMary Babb Randolph Cancer Center, School of Medicine, West Virginia University, Morgantown, West Virginia.
Ryan J IceMary Babb Randolph Cancer Center, School of Medicine, West Virginia University, Morgantown, West Virginia.
Brandon C JonesDepartment of Biochemistry, School of Medicine, West Virginia University, Morgantown, West Virginia.
Elena N PugachevaDepartment of Biochemistry, School of Medicine, West Virginia University, Morgantown, West Virginia. Mary Babb Randolph Cancer Center, School of Medicine, West Virginia University, Morgantown, West Virginia. epugacheva@hsc.wvu.edu.
West Virginia University · US

Funding

THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2001 to 2010
$22.8M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8M
The role of HEF1 protein in division and invasion of metastatic breast cancerR01CA148671 · NCI · WEST VIRGINIA UNIVERSITY · PI PUGACHEVA, ELENA NIKOLAEVNA · 2010 to 2020
$3.2M
COBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE IIIP30RR032138 · NCRR · WEST VIRGINIA UNIVERSITY · PI GIBSON, LAURA F. · 2011 to 2011
$1.1M
Visual Sonics Vevo 2100 Imaging SystemS10RR026378 · NCRR · WEST VIRGINIA UNIVERSITY · PI MARTIN, KAREN H · 2010 to 2010
$454k
NCI NIH HHS CA148671NCI NIH HHS R01 CA148671NCRR NIH HHS 5 P20 RR016440-09NCRR NIH HHS P20 RR016440NCRR NIH HHS P30 RR032138NCRR NIH HHS S10 RR026378NIGMS NIH HHS P30 GM103488
6 · The paper itself

Abstract

unlabelledThe dissemination of tumor cells relies on efficient cell adhesion and migration, which in turn depends upon endocytic trafficking of integrins. In the current work, it was found that depletion of the prometastatic protein, NEDD9, in breast cancer cells results in a significant decrease in individual cell migration due to impaired trafficking of ligand-bound integrins. NEDD9 deficiency does not affect the expression or internalization of integrins but heightens caveolae-dependent trafficking of ligand-bound integrins to early endosomes. Increase in mobility of ligand-bound integrins is concomitant with an increase in tyrosine phosphorylation of caveolin-1 (CAV1) and volume of CAV1-vesicles. NEDD9 directly binds to CAV1 and colocalizes within CAV1 vesicles. In the absence of NEDD9, the trafficking of ligand-bound integrins from early to late endosomes is impaired, resulting in a significant decrease in degradation of ligand-integrin complexes and an increase in recycling of ligand-bound integrins from early endosomes back to the plasma membrane without ligand disengagement, thus leading to low adhesion and migration. Reexpression of NEDD9 or decrease in the amount of active, tyrosine 14 phosphorylated (Tyr14) CAV1 in NEDD9-depleted cells rescues the integrin trafficking deficiency and restores cellular adhesion and migration capacity. Collectively, these findings indicate that NEDD9 orchestrates trafficking of ligand-bound integrins through the attenuation of CAV1 activity. IMPLICATIONS: This study provides valuable new insight into the potential therapeutic benefit of NEDD9 depletion to reduce dissemination of tumor cells and discovers a new regulatory role of NEDD9 in promoting migration through modulation of CAV1-dependent trafficking of integrins.

Indexed as

Adaptor Proteins, Signal TransducingBreast NeoplasmsCaveolin 1Cell AdhesionCell Line, TumorCell MovementEndosomesFemaleHumansIntegrinsPhosphoproteinsProtein TransportAdaptor Proteins, Signal TransducingCaveolin 1IntegrinsNEDD9 protein, humanPhosphoproteins

Identifiers

PMID25319010
PMCPMC4369181
OpenAlexW1966286335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.